Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...